EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort

N.S. Al Gazlan, A. Alwohaibi, A. Almazyad, M. Rudainee, M. Alharbi, A. AlTamimi, F. Faqihi, M.F. Aldawoud, A. Alturki, H.M.H.M. Bakhribah, A.K. Altwairgi

ESMO Open · 2026-05 · 11 · 107261

DOI: 10.1016/j.esmoop.2026.107261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Open, 2026-05. Verfasst von N.S. Al Gazlan und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gazlan, N. A., Alwohaibi, A., Almazyad, A., Rudainee, M., Alharbi, M., AlTamimi, A., Faqihi, F., Aldawoud, M., Alturki, A., Bakhribah, H., & Altwairgi, A. (2026). 310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort. ESMO Open, 11, 107261. https://doi.org/10.1016/j.esmoop.2026.107261

Vancouver

Gazlan NA, Alwohaibi A, Almazyad A, Rudainee M, Alharbi M, AlTamimi A, et al. 310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort. ESMO Open. 2026;11:107261. doi:10.1016/j.esmoop.2026.107261

BibTeX
@article{Gazlan2026,
  author = {Gazlan, N.S. Al and Alwohaibi, A. and Almazyad, A. and Rudainee, M. and Alharbi, M. and AlTamimi, A. and Faqihi, F. and Aldawoud, M.F. and Alturki, A. and Bakhribah, H.M.H.M. and Altwairgi, A.K.},
  title = {310P Neoadjuvant chemotherapy in ER+/HER2-negative or HER2-low early breast cancer: pCR, compliance, and predictors in a single-center cohort},
  journal = {ESMO Open},
  year = {2026},
  volume = {11},
  pages = {107261},
  doi = {10.1016/j.esmoop.2026.107261}
}
Kostenlos starten →